|Bid||2.20 x 3600|
|Ask||3.68 x 500|
|Day's Range||2.60 - 2.85|
|52 Week Range||1.90 - 8.50|
|PE Ratio (TTM)||-2.35|
|Earnings Date||Nov 10, 2016 - Nov 14, 2016|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||7.33|
NEW YORK, NY / ACCESSWIRE / July 18, 2017 / Neither Soligenix nor Aurinia had any remarkable news on Monday to account for their big share price jumps. Soligenix did, however, get coverage initiated on ...
PRINCETON, N.J., July 6, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will be presenting an overview of its SGX94 (dusquetide) technology platform on July 13, 2017 at the Drug Discovery and Therapy World Congress (DDTWC) taking place in Boston, MA from July 10 - 13, 2017. The presentation will address dusquetide's novel mechanism of anti-inflammatory, anti-infective and tissue-healing action, as well as final results from its SGX942 Phase 2 clinical trial in oral mucositis. Modulation of Innate Immunity in the Treatment of Inflammation-Driven and Infection-Driven Disease presented by Dr. Oreola Donini, Chief Scientific Officer on July 13, 2017 at 1:45 pm. The abstract is available here.
PRINCETON, N.J., June 21, 2017 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has exercised an option for the evaluation of RiVax® to fund additional animal efficacy studies. The exercised option for contract #HHSN272201400039C will provide Soligenix with approximately $2M in additional funding, bringing the total amount awarded to date under this contract to $18.7M. If all contract options are exercised, the total award of up to $24.7 million will support the preclinical, manufacturing and clinical development activities necessary to advance heat stable RiVax® with the US Food and Drug Administration (FDA).